The Pulse Report 2024
The Pulse: Global R&D Insights in Pharmaceuticals
Insights from 150 global drug development leaders illuminate industry trends, challenges and sentiments
✓
The impact of rising costs on clinical trials
✓
Technological innovations driving drug development
✓
Shifts in outsourcing strategies
Sneak peek
Three major trends shaping the drug development industry
AI adoption is accelerating
AI is transforming the industry, with 66% of large companies leveraging it for efficiencies in recruitment, advanced analytics, and real-world data/evidence (RWD/RWE). This reflects a significant increase in the adoption of AI technologies since 2023.
Trial complexity is escalating
Managing the increasing complexity of clinical trials is a growing challenge. Nearly two in five companies cite this as a major concern, as intricate protocol designs and regulatory requirements continue to add layers of difficulty and extend development timelines.
Speeding up development timelines is crucial
Accelerated development timelines are becoming increasingly important, with nearly half of companies reporting longer timelines compared to two years ago. This trend underscores the industry’s efforts to streamline processes and reduce time-to-market for new therapies, despite the growing complexity of trials.
What is the current state of the clinical research industry, and where is it headed? We asked 150 global leaders.
Get the full report by filling out the information below.